Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From a practitioner view, it might be worth emailing them.
From an investor view, $15m pre orders for Discov-R suggests a ready market.
GLA
Nigel , I assume you won't be investing then ....thanks for your wisdom although mostly over my head . Market leader with a huge market that's all I need to know
Cheers
Of course it is better than trolly supplementary oxygen. When locked down I invented a BiPAP system using commercially available components, it was going quite well until consulting with experienced critical care nurses. Giving oxygen at the intensity of CPAP, BiPAP or intubation is both a science and an art: the art of invasive ventilation is to persuade a patient that you are about to knock them out with Midazolam, ok create a decent level of sedation and anterograde amnesia. Then you are going to give a neuromuscular blockade. The science is even more complex and this is why the 'Nightingale' hospital was such a useless idea. Maybe they could have been useful for basic nursing and supplementary 02 only. HMG had to have some sort of plan though.
Obviously this device is easy to use and completely non intimidating: I bought an 02 concentrator to conduct my experiments with. It is about 30-35kg, runs on mains power but can yield 10 litres/min continuous flow.
Its much better than carrying a trolley and a metal cyclinder up Snowden.
Discov-r is the inflection point moving from 0.8l for the I-plor to 2L. The market is now much bigger and the product is a world leader.
GLA
Still on track and outperforming. SP will fill the recent fall pretty quickly.
At 2 litres/min how much difference will this gadget make if attempting, let us say, the Snowdon Horse Shoe (inc Crib Goch). The vast majority of patients with COPD have at least one co-morbidity and many have five or greater! Here is a para from the GP journal.
Results From the total sample, 51 928 patients had COPD (4.1%). Of these, 86.0% had at least one comorbidity, compared with 48.9% of people without COPD. Of those with COPD, 22.3% had ≥5 comorbid conditions.
Of course COPD is not the only condition which requires supplementary O2 but if I was up for an investment here (it's possible) I would need to see better performance, a lower mcap and better fundamentals. This could happen...
Just FYI
REPLY FROM BELL
Thank you for your enquiry.
The Company released further information today regarding initial production of the DISCOV-R(tm), which will commence this week. It also guided that full-scale production is being planned in conjunction with Innomax in response to the significant preliminary demand already received by the Company.
This is in line with prior guidance in the Unaudited Interim Results for the six months ended 30 June 2023, which was published on 13 September 2023 and stated in the Chairman's Statement that the Company started its premarket evaluation of the DISCOV-R portable oxygen concentrator in Q2 2023, with full commercialisation anticipated in H2 2023.
Today's full announcement can be found online at the following link for reference: https://www.XXXXXXXXX.com/news-article/BELL/belluscura-receives-approval-in-hong-kong/16139174.
If you have any further questions, please let us know.
Nice to reply quickly. Nothing new above that announced. Seems like a delay to get Innomax chugging it out swiftly.
Seaman…. My wife tells me that most days
I do balance it by finding the funny in everything….
Boyg, and k.not going to shoot you down as we all have opinions but what I will say is you need to find something positive to hold onto buddy as you Seem a very glass half empty kind a guy
Wishing everyone all the best
Ok…. So I read the announcement and it’s good news. But as with all things Belluscura we have to look at what’s really happening.
Now don’t shoot me. But when 1200 sold units and 1100 soon to be posted equates to £400g then I look for what this is truly saying.
Firstly they said 6500 units ordered of new discovery-r. They said could be many more and they said some rationing to manage expectations. All makes sense
We Hear no Hong King numbers on orders. One unit would validate the RNS.
Then we look at production. Again one unit would be enough to say production starts. Initial production begins this week! Initial???
Followed by full scale production being planned with Innomax.
For that I read ‘delay’ full scale production.
Last we heard it was full steam ahead discov-r in USA. Innomax to produce Xplor and roll out. Then Innomax will join them producing discov-r.
What I was expecting was full production of discov-r with expected production numbers. Nope
Then we hear ‘all patients providing favourable feedback’
That reads that they would rather use it than not use it! Possibly there are tweaks needed? So it is delayed?
But this announcement felt like ‘look over here’ and pay no attention to that over there.
It’s a very negative interpretation but until someone tells me how 1200 units = 400g I will look for what is not being said
I can see this even dropping on what, on the face of it, is good news!!
Let the shooting commence
Useability study completed. Production starts this week. PO and license approved in Hong Kong.
We can now use all of that inventory.
GLA
I have emailed belluscura. No reply yet. Simple question q3 or delayed.
The other one hasn’t floated yet! Currently long overdue and not sure it’s looking good! No news at all for long time. That will hurt hard
@theboyg. I am hoping that if credit is needed the bank should be able to provide credit on more attractive terms than dilution offers given that orders are in. There probably is need for further funds but may not be need for further dilution.
Good luck with BELL and your other 'roll of the dice' too - would be interested to know who the other is.
Boyg , assuming you have sent correspondence to Bell and asked the question
Watched vox last night. Pal said that discov-r was not due out until Q4. That’s not public?? They defo said it was Q3!!! Unless there are unknown delays
Well, 6 days max for discov-r to be unleashed! If that’s delayed this drops into the 20s.
The more I have thought, the more money seems essential. The x-plor wasn’t selling fast. The ones they did sell nobody seems to have paid for based on any revenue figure you quote.
So I can only assume delays are hopefully with both eyes facing forward to discover-r. Throw everything there. This has been on radar for long time. Orders are good if you can place value on that statement. China deal guaranteed income. Lots of promises for tomorrow with unfulfilled expectations in the past.
Someone doesn’t like the news of half year stats and there is validity in that I think.
I’m here to £1 to recoup losses. It’s one of two last rolls of the dice for me. So I’m staying. I understand those who left.
Bob R talked of more news in next two months. China deal announced v swiftly after so you would expect more beyond that perhaps?
‘Rationing’ of orders was also mentioned in vox interview I think? So they must get this order number satisfied ASAP. That will mean money and people at full capacity. Inventory totals hopefully only applies to useful inventory and not material that was for xplor and no use to discov-r
The price may be artificially reduced to make any financing attractive! It will dilute what we have but hopefully we can get involved at the reduced price? Whatever the price this must be a last raise. Any more and the product has failed.
They seem well placed… as well as ever. As usual, they just need to make the Damn things.
@theboyg. I believe you can join simply by providing your e-mail address.
Today he offered his opinion that whilst it will be a close run thing, BELL may not need to raise more cash. His forecast is that $cash will be at its lowest in Q3 2023 at 450k, rising to 720k in Q4. He also forecasts cash of $4.61m by Q4 2024 which are the sort of numbers we want to see. No guarantees he is right of course but we may almost be over the worst in cash terms?
That may explain the dump! It appears the link is for members! Anyone able to paste best bits here?
I’d like to say I have faith here
But I do feel let down. I feel like the bloke staring at the sweets through the window
But for me 90% of hard yards are done here! Hope xplor lessons are applied to discover-r and there are no faults. 55 million over ten years with new deal. Other chap said $250 a unit so at $5million a year that’s 20,000 units a year.
Lots said about NOMAD app but it’s capabilities seemed very one dimensional and not too much of a wow
Units and r&d are the future. Small company with little funds. There is nothing beyond discov-r yet. But that may be enough if patents are good.
The price seems wrong. We know we are the last to know but on the law of averages not everything I invest in can go so badly t*ts up… or can it
I wish the company well and GLA
I read the Oak Bloke's analysis and sounds pretty reasonable to me. Although at end he suggests a 15/20 PE ratio which seems highly conservative. Remember a more mature stock like Nvidia has a PE of 179 currently.
One look at this fellow Tom Winnifrith's bio shows that he is complete joke.
Interesting that Tom Winnifrith is slating BELL because they will need funds to deliver a substantive order. In contrast, he has been pumping a stock he holds Skinbiotherapeutics (SBTX) which will have to raise before the end of this year. They burn about £3m and have next to zero revenues.
BELL have guaranteed and substantial orders unlike SBTX who, if they don't raise, are relying on getting a licensing deal is unlikely in the extreme as they won't have completed consumer testing. Not a position the markets will like but does TW raise as an issue of concern - not in the slightest. Complete double standards. Looks like he might be helping out some shorting pals who have an obvious short position in BELL based on their posts on the other site. They will have to unwind at some stage.
Is obtaining funding on AIM right now easy? Not necessarily but much easier for a Company with a high-demand USP commercial product and significant accompanying orders (BELL) compared to TW's stock, SBTX, which will have to raise this year and currently has less revenue than a struggling corner shop. Shameful journalism in my view.
Haha, that's funny, thanks EyesOfBlue. I'm surprised he carries that kind of clout.
Assume TW is that flesh-crawling Piers-Moron-Robert-Peston mash up … Tom Winnifrith? Sets himself up as some sort of Defender if Investors but they just spout gallons of badly written pump n dump nonsense. Allegedly.
@Agricore. Thanks for the link, which makes for a good read. The Oak Bloke seems very upbeat and provides explanations, at least in part, for the Low H1 revenue, including allocation of H2 costs within H1 figures. I certainly hope he is right and no capital raise is required - bankers should be willing to satisfy needs with short term credit?
Valid queries raised on this board though re the absence of information regarding the required change to specification and halt in production. I wonder if that point is in any way linked to the 'discount' applied to the early sales?